#SARSCoV2#Omicron harbors a staggering 37 amino acid mutations in the spike with 15 of them in the receptor-binding domain (RBD), which is the main target of neutralizing antibodies. The number and positions of these mutations is concerning for tropism & immune evasion.
2/8
We found that the #SARSCoV2#Omicron RBD has ~2.5-fold enhanced ACE2 binding affinity, relative to the Wuhan-Hu-1 RBD, similar to what we previously showed for the Beta variant of concern.
We discovered that the #SARSCoV2#Omicron RBD, but not Alpha or Beta RBDs, bound mouse ACE2, likely due to Q493R which is similar to Q493K isolated upon mouse adaptation by @Baric_Lab
These data *putatively* reflect #Omicron expanded tropism
4/8
#SARSCoV2#Omicron immune evasion reduces plasma neutralizing activity up to 57x (convalescent) and up to 30-40x for Pfizer, Moderna or Astrazeneca vaccinees.
No neutralizing activity left with J&J (1x), Sputnik and Sinopharm for most subjects analyzed.
5/8
#SARSCoV2#Omicron mutations knock out 7 out of 8 monoclonal antibodies currently used in the clinic. Only S309, the parent of VIR-7832, retain neutralizing activity, with ~3x reduction relative to Wuhan-Hu-1.
A few other broadly neutralizing sarbecovirus antibodies are inhibiting #SARSCoV2#Omicron, including S2X259, S2H97 and S2K146. This is good news and shows that targeting conserved sarbecovirus RBD epitopes provides resilience to viral evolution!
We followed 4 cohorts longitudinally for up to 6 months:
-Delta breakthrough (vaccinated then infected)
-subjects infected and then vaccinated (2x and 3x)
-vaccinated-only (2x and 3x)
-infected-only
in collaboration with @HelenChuMD and her HAARVI team.
2/15
Serum IgG binding titers correlated with the number of SARS-CoV-2 spike 'exposures' through vaccination and/or infection and were therefore highest for 3x vaccinated subjects (infected or not) and Delta breakthrough cases.
Have you heard of the recently discovered 8th human-infecting #coronavirus designated CCoV-HuPn-2018?
We reveal the architecture of its spike (ie infection machinery), receptor usage and antigenic properties!
CCoV-HuPn-2018 is a canine-feline recombinant alpha-#coronavirus isolated from the respiratory swab of a child hospitalized with pneumonia, indicating that more coronaviruses are spilling over to humans than previously appreciated.
We determined #cryoEM structures of the CCoV-HuPn-2018 spike in two markedly different conformational states which we propose to correspond to two snapshots of viral entry.
We show that vaccine-elicited neutralizing activity is reduced against delta and kappa and even more against delta+ relative to the vaccine-matched pseudovirus. Delta+ reduces neutralization ~ to B.1.351 (beta) which has the greatest magnitude of immune evasion thus far.
2/9
Half of the J&J-vaccinated individuals in our panel had no residual variant neutralization. Although we only analyzed neutralizing antibodies (T cells are also key players for in vivo protection), this supports offering second vaccine dose
The #SARSCoV2 CAL20.C (B.1.427/B.1.429) variant is skyrocketing in California. We describe how it evades the host immune response with @DavideCorti6@LucaPiccoli9
The #SARSCoV2 CAL20.C (B.1.427/B.1.429) variant comprises 3 spike mutations: S13I, W152C & L452R reducing plasma neutralizing activity by ~3x and ~5x for vaccine- and infection-elicited antibodies (Abs), compared to the 'ancestral' virus.
2/7
The neutralization potency of 1/3 of RBD Abs is reduced or abrogated by the L452R spike mutation present in #SARSCoV2 CAL20.C (B.1.427/B.1.429), including clinical-stage antibodies such as Eli Lilly LY-CoV555 (bamlanivimab) & Celltrion CT-P59 (regdanvimab)
We report an analysis of #SARSCoV2 spike NTD antigenic sites targeted by monoclonal antibodies (mAbs) in #COVID19 patients in collaboration with @DavideCorti6 and Matteo Samuele Pizzuto @Vir_Biotech
We found that NTD-specific mAbs account for 6-20% of mAbs cloned from memory B cells in #COVID19 patients and that the most potent of them neutralize #SARSCoV2 as efficiently as ultrapotent RBD-specific mAbs and trigger Fc-mediated effector functions effectively.
2/10
We delineated an antigenic map of the #SARSCoV2 spike NTD using #cryoEM (including a 2.2Å structure) and binding assays revealing the presence of a site of vulnerability recognized by all potently neutralizing mAbs described thus far.
We discovered a neutralizing mouse monoclonal antibody (B6) targeting the coronavirus spike fusion machinery (S2 subunit) in collaboration with @McGuire_Lab
We identified by cryoEM that B6 recognizes the spike stem helix and cross-reacts with at least 8 distinct coronavirus spikes including those of the three highly pathogenic (#SARSCoV2, SARS-CoV and MERS-CoV) and the two endemic (OC43 and HKU1) human β-coronaviruses.
2/6
B6 broadly neutralizes spike-mediated entry into cells of distantly related coronaviruses including OC43 (lineage A) as well as MERS-CoV and HKU4 (lineage C) with comparable potencies.